Navigation Links
Mayo Clinic study finds FDA warning against antinausea drug droperidol unnecessary
Date:9/28/2007

ROCHESTER, Minn. -- A Mayo Clinic review of patients responses to a drug used to control nausea and vomiting during anesthesia for general surgery questions a U.S. Food and Drug Administration (FDA) warning against the drugs use. This study appears in the current issue of the journal Anesthesiology.

The FDA warning against droperidol was prompted in 2001 over concerns that the drug contributed to potentially fatal heart rhythm abnormalities. Mayo Clinic compared 139,932 patients responses before the warning was issued (and droperidol was used) and found no proven cases of complications directly attributable to droperidol. In comparison, after the FDA warning, two of 151,256 patients had poor heart rhythm while receiving other, more expensive medication alternatives. The percentage of patients who received droperidol was 12 percent prior to the warning and 0 percent after placement of the warning.

Based on their findings, Mayo Clinic anesthesiologists conclude that the FDA warning against droperidol is unnecessary. They call for other investigators to study the topic to determine if further inquiry supports that conclusion.

In our study, we obtained results that were just the opposite of what the FDA action would predict. We actually had fewer complications with droperidol, explains Gregory Nuttall, M.D., the lead Mayo Clinic anesthesiologist on the study. In our experience, low-doses of droperidol used by a skilled team are the safer and more effective agent for controlling nausea and vomiting, which is why we are making plans to resume its low-dose use in select patients in the cardiac Intensive Care Unit.

Significance of the Mayo Clinic Study

The Mayo Clinic study is the first large, statistically well-controlled study of patient responses to droperidol at a single medical center over a long time (three years) that included treatment before and after the FDA warning. As such, it provides the strongest scientific evidence to date for the performance of droperidol and alternatives.

Background

Since the FDA warning about droperidol was issued in 2001, reports in medical literature have questioned its accuracy and usefulness. It has been well established that all drugs used to prevent or control nausea prior to anesthesia use in general surgery also can have the negative side effect of prolonging a particular kind of abnormal heart rhythm known as long QT. Practitioners didnt understand why just one drug was singled out for a warning.

Dr. Nuttall explains: There is a basic question: Is droperidol really that bad when compared to all the other drugs" I worked with droperidol, and I never saw a problem at the low doses we are talking about. After the warning, we all went to the more expensive drugs. Then we encountered the problem that none address rescue therapy well that means once youre sick, you're stuck; the drugs don't work well. In addition, the data upon with the FDA based its decision came from case reports. Statistically, these are not as strong as controlled, systematic reviews of a large number of patient experiences at a single medical center using the same protocols.

Implications for Patient Care

The Mayo Clinic team hopes another large controlled study will determine if the Mayo results can be validated. If they are validated, it might then prompt the FDA to revoke the warning against droperidol.

In the meantime, Dr. Nuttall recommends that each institution approach low-dose droperidol use with caution in a heart-monitored setting and only with advice from highly trained and experienced anesthesiologists. Our only interest here is in seeing that patients get the safest and most beneficial treatment, Dr. Nuttall says.


'/>"/>

Contact: Amy Tieder
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. How do patients benefit of clinical trials
3. Magnetic resonance angiography in clinical medicine
4. Clinical trials need to be more frank
5. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
6. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
7. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
8. Clinical Comparisons Between ADHD Drugs Are Less
9. Specialized Clinics For Manipurs AIDS Patients
10. Outsourcing clinical trials to India
11. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
Breaking Medicine Technology: